340B Report Publisher and Chief Executive Officer Ted Slafsky says in his latest column for Omnicell’s blog that “all signs foretell a Republican takeover of the House and a very good possibility of the GOP assuming control of the closely divided Senate” after the November 2022 elections for Congress.
“This will have significant implications for the 340B drug pricing program, not only for policy but also for the key players setting the agenda,” Slafsky says.
340B Report Publisher and Chief Executive Officer Ted Slafsky says in his latest column for Omnicell’s blog that “all signs foretell a Republican takeover of the House and a very good possibility of the GOP assuming control of the closely divided Senate” after the November 2022 elections for Congress.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
